Premium
Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by 18 F‐labelled fluorodeoxyglucose positron emission tomography‐ MRI
Author(s) -
Ito Jun,
Nogami Munenobu,
Morita Yasuko,
Sakaguchi Kazuhiko,
Komada Hisako,
Hirota Yushi,
Sugawara Kenji,
Tamori Yoshikazu,
Zeng Feibi,
Murakami Takamichi,
Ogawa Wataru
Publication year - 2021
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.14262
Subject(s) - metformin , lumen (anatomy) , fluorodeoxyglucose , positron emission tomography , medicine , nuclear medicine , diabetes mellitus , standardized uptake value , small intestine , endocrinology
Aim To investigate the relationships between various clinical variables and the metformin‐induced accumulation of fluorodeoxyglucose (FDG) in the intestine, with distinction between the intestinal wall and lumen, in individuals with type 2 diabetes who were receiving metformin treatment and underwent 18 F‐labelled FDG ([ 18 F]FDG) positron emission tomography (PET)‐MRI. Materials and Methods We evaluated intestinal accumulation of [ 18 F]FDG with both subjective (a five‐point visual scale determined by two experienced radiologists) and objective analyses (measurement of the maximum standardized uptake value [SUV max ]) in 26 individuals with type 2 diabetes who were receiving metformin and underwent [ 18 F]FDG PET‐MRI. [ 18 F]FDG accumulation within the intestinal wall was discriminated from that in the lumen on the basis of SUV max . Results SUV max for the large intestine was correlated with blood glucose level (BG) and metformin dose, but not with age, body mass index, HbA1c level or estimated glomerular filtration rate (eGFR). SUV max for the small intestine was not correlated with any of these variables. Visual scale analysis yielded essentially similar results. Metformin dose and eGFR were correlated with SUV max for the wall and lumen of the large intestine, whereas BG was correlated with that for the wall. Multivariable analysis identified metformin dose as an explanatory factor for SUV max in the wall and lumen of the large intestine after adjustment for potential confounders including BG and eGFR. Conclusions Metformin dose is an independent determinant of [ 18 F]FDG accumulation in the wall and lumen of the large intestine in individuals treated with this drug.